A Randomized, Controlled, Double-blind Study to Evaluate Efficacy and Survival of Combining Nimotuzumab Plus Concurrent Chemo-radiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma
Phase of Trial: Phase III
Latest Information Update: 25 Apr 2016
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin; Paclitaxel
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 19 Apr 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 08 Apr 2015 New trial record
- 07 Apr 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.